Pay in 4 interest-free payments of $5.28 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Semaglutide treatment has reshaped the conversation around obesity management, offering patients new hope in tackling weight-related conditions with real, measurable results
Proven results that are backed by science
COA Tirzepatide 5mg Certificate Tirzepatide 5mg The Next-Generation Solution for Type 2 Diabetes and Weight Management Tirzepatide 5mg is a groundbreaking injectable medication that offers a dual-action mechanism uniquely designed to improve blood sugar control and support meaningful weight loss
Across four JARDIANCE outcome trials, lower limb amputation event rates were 4.3 and 5.0 events per 1,000 patient-years in the placebo group and the JARDIANCE 10 mg or 25 mg dose group, respectively, with a HR of 1.05 (95 % CI) (0.81, 1.36)
Understanding these reactions and appropriate management strategies is essential for maintaining treatment adherence and patient comfort
It is not FDA approved as of 2026 and is in Phase 3 trials for obesity
